Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcomas

Trial Profile

A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcomas

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APX 005M (Primary) ; Doxorubicin (Primary)
  • Indications Liposarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2019 Status changed from not yet recruiting to recruiting.
    • 28 Feb 2019 Planned initiation date changed from 1 Dec 2018 to 1 Apr 2019.
    • 20 Dec 2018 According to an Apexigen media release, the company has collaborated with Columbia University Irving Medical Center for the conduct of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top